Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy

Trial Title: Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy

NCT ID: NCT05887245

Condition: Renal Cell Carcinoma
Kidney Neoplasm
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases

Conditions: Official terms:
Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Urogenital Neoplasms
Urologic Neoplasms
Kidney Diseases

Conditions: Keywords:
Partial Nephrectomy
Adherent Perinephric Fat

Study type: Observational

Overall status: Recruiting

Study design:

Time perspective: Prospective

Summary: The aim of this study is to gain a better understanding of the phenomenon of adherent perinephric fat (APF), which occurs in some patients undergoing partial nephrectomy (PN). This phenomenon, so-called "toxic fat", is a commonly recognized problem among urologists, but its significance has not yet been fully understood. The study aims to identify new clinical risk factors for APF occurrence and evaluate its impact on functional, perioperative, and oncological treatment outcomes. The study will be conducted on patients who are qualified for PN surgery. Prior to the surgical procedure, venous blood will be collected, which will be used for various measurements, such as blood morphology, kidney parameters, inflammation markers, liver function tests, glucose, and lipid profile. In addition, medical data will be collected concerning the patient's overall health, observed changes in the kidney, perioperative course, hospitalization, and histopathological characteristics of the tumor. After treatment, patients will be followed up for up to 60 months. The knowledge gained from this study can significantly assist in making decisions about surgical treatment and thus contribute to improving the treatment outcomes of patients with kidney tumors.

Detailed description: Patients qualified for partial nephrectomy surgery based on radiological diagnosis of kidney tumor will be prospectively identified. Thirty milliliters of venous blood will be collected one day prior to the procedure. Blood samples will be sent to the laboratory, where, in addition to the standard preoperative tests (blood count, creatinine, urea, fasting glucose), the following parameters will be determined: C-reactive protein, ferritin, total cholesterol, low density lipoprotein, high density lipoprotein, and triglycerides. At the time of patient enrollment in the study, a clinical and demographic interview will be conducted. In addition, the hospital's electronic medical records will be used to obtain preoperative conventional imaging test results related to tumor characteristics. During the treatment, perioperative parameters will also be collected, including the presence of APF defined intraoperatively by the surgeon. APF is defined as "perinephric fat adherent to the renal parenchyma, making renal dissection difficult" with the presence defined by the surgeon as 1 - present, 0 - absent. The patient's participation in the study will not affect the type or technique of the surgery, and therefore, the risk of complications. After obtaining the histopathological result, data regarding the removed tumor will be collected. During the observation period (6, 12, 24, and 60 months after treatment), oncological and functional outcomes will be assessed and recorded. The observation will be conducted according to the treating physician's recommendations, in accordance with current medical knowledge, and its modification is not the subject of this study. Patient data will be collected and stored in an electronic database. The assessment of the relationship between the various blood parameters, demographic characteristics (age, gender), clinical characteristics (such as BMI, presence of metabolic syndrome, tumor size), and the presence of APF will be performed using univariate analysis (Chi-square, univariate logistic regression) and multivariate analysis (logistic regression models). When evaluating the impact of APF on perioperative and oncological outcomes, confounding variables (such as tumor stage, surgical method, surgeon) will be taken into account when creating predictive models.

Criteria for eligibility:

Study pop:
Patients with a radiological diagnosis of kidney tumor referred for surgical treatment with partial nephrectomy will be eligible.

Sampling method: Probability Sample
Criteria:
Inclusion Criteria: - Patients qualified for partial nephrectomy by open, laparoscopic, or robotic method - Tumor stage cT1a-cT1b according to Tumour Node Metastasis classification - Age ≥ 18 years - Written consent to participate in the study Exclusion Criteria: - Patient does not give consent to participate in the study - Patients with recurrent kidney cancer, or who have undergone other surgeries within the kidney - Lack of preoperative imaging available for assessment - Missing medical documentation that prevents data analysis

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: European Health Centre, Second Department of Urology, Centre of Postgraduate Medical Education

Address:
City: Otwock
Zip: 05-400
Country: Poland

Status: Recruiting

Contact:
Last name: Łukasz Mielczarek, MD

Phone: 22 710 30 42

Phone ext: +48
Email: lukasz.mielczarek@ecz-otwock.pl

Investigator:
Last name: Łukasz Mielczarek, MD
Email: Sub-Investigator

Start date: April 17, 2023

Completion date: January 1, 2030

Lead sponsor:
Agency: Centre of Postgraduate Medical Education
Agency class: Other

Source: Centre of Postgraduate Medical Education

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05887245